|1.||Masliah, Eliezer: 68 articles (11/2015 - 02/2002)|
|2.||Trojanowski, John Q: 44 articles (10/2015 - 02/2002)|
|3.||Rockenstein, Edward: 39 articles (01/2015 - 03/2002)|
|4.||Lee, Virginia M-Y: 39 articles (01/2014 - 05/2002)|
|5.||Fink, Anthony L: 37 articles (01/2012 - 01/2002)|
|6.||Iwatsubo, Takeshi: 35 articles (11/2010 - 02/2002)|
|7.||Giasson, Benoit I: 33 articles (05/2010 - 05/2002)|
|8.||Uversky, Vladimir N: 31 articles (01/2012 - 01/2002)|
|9.||McLean, Pamela J: 30 articles (02/2015 - 11/2002)|
|10.||Hyman, Bradley T: 28 articles (01/2014 - 05/2002)|
|1.||Parkinson Disease (Parkinson's Disease)
05/01/2008 - "These findings demonstrate that alpha-synuclein acts as a potent inflammatory stimulator of microglial cells, and that inhibitors of such stimulation might be beneficial in the treatment of Parkinson's disease and other synucleinopathies."
07/15/2012 - "The aggregation of alpha-synuclein (AS) is pivotally implicated in the development of Parkinson's disease (PD), inhibiting this process might be effective in treating PD. "
08/01/2004 - "A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders."
09/01/2008 - "Because of the worldwide research efforts conducted over the last two decades and the discovery of the alpha-synuclein-encoding SNCA gene as a cause of rare familial Parkinson's disease, the MSA field has seen advances on three fronts: the identification of its principal cellular target, that is, oligodendrocytes; the characterization of alpha-synuclein-rich glial cytoplasmic inclusions as a suitable marker at autopsy; and improved diagnostic accuracy in living patients resulting from detailed clinicopathological studies. "
05/01/2014 - "Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease."
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
12/01/2015 - "Our study also provides evidence for early microglial activation prior to alpha-synuclein-independent neuronal cell death in GBA1 deficiency and suggests upregulation of miR-155 as a common denominator across different neurodegenerative disorders. "
03/01/2008 - "The data presented in this study demonstrate that an apoptotic event caused by a "physiological" trigger, such as neuronal membrane repolarization of cultured cerebellar granule neurons, induces alpha-synuclein intracellular redistribution and aggregation, two molecular events reminiscent of those occurring in different human neurodegenerative diseases all characterized by alpha-synuclein-positive inclusions. "
09/01/2007 - "The aim of this study was to assess the effects of DR on expression of alpha-synuclein, a presynaptic protein involved in pathogenesis of Parkinson's and some other neurodegenerative diseases, in the cortex and hippocampus of adult, middle-aged, late middle-aged, and aged rats. "
03/30/2004 - "Taken together, the data provided in this study indicate that PcTS/PcTS-Cu(2+) could be considered as possible candidates for the development of therapeutic or prophylactic strategies against the alpha-synuclein-related neurodegenerative disorders."
07/01/2003 - "Genetic and protein studies have indicated abnormalities in alpha-synuclein in neurodegenerative diseases. "
02/01/2008 - "Alpha-synuclein and tau deposition in the striatum were rare in both groups, but the Abeta burden was significantly greater in the striatum of PD cases with dementia than present in the nondemented PD group. "
08/01/2001 - "The load of alpha-synuclein pathology was significantly greater in the demented patients versus non-demented subjects indicating that alpha-synuclein pathology is indeed of importance in the pathogenesis of dementia."
12/01/2013 - "We report three patients with PD who presented striking psychiatric manifestations along with mild cognitive decline not progressing to dementia across the course of disease and in which postmortem neuropathological study revealed, besides alpha-synuclein inmunoreactive Lewy-body pathology, concomitant four-repeat tau positive argyrophilic grain pathology. "
06/01/2010 - "The study suggests that reduced levels of CSF alpha-synuclein in DLB may reflect the accumulation of alpha-synuclein with Lewy pathology in the brain and that quantification of CSF alpha-synuclein helps in the differentiation of DLB from AD and other dementias in combination with Abeta42 and tau analysis."
08/01/2009 - "This study found that both LC3-II and beclin were significantly increased in brains from humans with Dementia with Lewy bodies and transgenic mice overexpressing mutant alpha-synuclein, as compared with respective controls, suggesting that macroautophagy is induced to remove alpha-syn, particularly oligomeric or mutant forms. "
|4.||Huntington Disease (Huntington's Disease)
07/28/2000 - "Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models."
06/01/2007 - "Three SMERs induced autophagy independently of rapamycin in mammalian cells, enhancing the clearance of autophagy substrates such as mutant huntingtin and A53T alpha-synuclein, which are associated with Huntington's disease and familial Parkinson's disease, respectively. "
02/23/2007 - "Trehalose-induced autophagy enhanced the clearance of autophagy substrates like mutant huntingtin and the A30P and A53T mutants of alpha-synuclein, associated with Huntington disease (HD) and Parkinson disease (PD), respectively. "
03/01/2010 - "In yeast models of Huntington's disease, Hsp104 is required for the aggregation and toxicity of polyglutamine (polyQ), but the expression of Hsp104 in cellular and animal models of Huntington's and Parkinson's disease protects against polyQ and alpha-synuclein toxicity. "
07/28/2000 - "To investigate other protein components of polyglutamine aggregates, cerebral cortex and striata from patients with Huntington's disease and full-length cDNA transgenic mouse models for this disease were examined immunohistochemically for alpha-synuclein reactivity. "
|5.||Multiple System Atrophy
03/09/2007 - "To investigate the precise role of Hsc70 and Hsp70 in patients with multiple system atrophy (MSA), which is another alpha-synuclein-related disease, we performed immunohistochemical studies on Hsc70 and Hsp70 using autopsied brains from 7 normal subjects and 15 patients with MSA. "
10/01/2006 - "In this study, we measured the plasma alpha-synuclein levels in 105 patients with PD, 38 patients with multiple system atrophy (MSA), and 51 age-matched controls. "
02/01/2003 - "In this semiquantitative study based on 26 post-mortem cases, we describe the involvement of precerebellar nuclei in multiple system atrophy (MSA), a progressive degenerative disorder of the human central nervous system characterized by abnormal, argyrophilic and alpha-synuclein immunopositive intracellular inclusions within selectively vulnerable oligodendrocytes and nerve cells. "
10/01/2002 - "Alpha-synuclein immunoreactivity and ultrastructural study of glial cytoplasmic inclusions in multiple system atrophy."
07/19/2002 - "This cell system of oligodendroglial alpha-synuclein expression is a useful system to study alpha-synuclein metabolism in the cell type affected in multiple system atrophy. "
|1.||Proteins (Proteins, Gene)
|2.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|3.||Amyloid (Amyloid Fibrils)
|7.||Molecular Chaperones (Chaperone, Molecular)
|5.||Transplantation (Transplant Recipients)